Qiagen Share Price Nasdaq
Equities
NL0012169213
Biotechnology & Medical Research
Sales 2024 * | 2.01B 168B | Sales 2025 * | 2.14B 178B | Capitalization | 9.67B 807B |
---|---|---|---|---|---|
Net income 2024 * | 404M 33.72B | Net income 2025 * | 450M 37.56B | EV / Sales 2024 * | 4.98 x |
Net Debt 2024 * | 325M 27.13B | Net cash position 2025 * | 206M 17.23B | EV / Sales 2025 * | 4.43 x |
P/E ratio 2024 * |
23.9
x | P/E ratio 2025 * |
21.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.67% |
Latest transcript on Qiagen
Managers | Title | Age | Since |
---|---|---|---|
Thierry Bernard
CEO | Chief Executive Officer | 60 | 01/15/01 |
Metin Colpan
FOU | Founder | 69 | 29/96/29 |
Roland Sackers
DFI | Director of Finance/CFO | 56 | 01/99/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 01/11/01 | |
Metin Colpan
FOU | Founder | 69 | 29/96/29 |
Lawrence Rosen
CHM | Chairman | 66 | 26/13/26 |
1st Jan change | Capi. | |
---|---|---|
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |